*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Acalabrutinib, Afatinib, Axitinib, and Cabozantinib S-Malate are high-purity kinase inhibitors used in oncology. <strong>Acalabrutinib</strong> (CAS 1205678-29-2) targets BTK; <strong>Afatinib</strong> (CAS 459890-48-1) inhibits EGFR/HER2; <strong>Axitinib</strong> (CAS 950247-67-9) blocks VEGFR; <strong>Cabozantinib S-Malate</strong> (CAS 1232405-77-6) targets MET/VEGFR. Core synthesis involves advanced organic coupling and salt formation.</p>
<h3>Application</h3>
<ul>
<li>Pharmaceutical manufacturing for chronic lymphocytic leukemia treatment.</li>
<li>Oncology R&D for non-small cell lung cancer therapy.</li>
<li>Renal cell carcinoma clinical trial supply chains.</li>
<li>Gastric cancer targeted drug development programs.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly store below -20°C in dry, inert atmospheres. Handle with PPE to prevent dermal absorption. Clinical use requires monitoring for hypertension and bleeding risks under professional supervision.</p>